Actively Recruiting
Open-Label Study of Subcutaneous Guselkumab to Evaluate Safety and Efficacy in Indian Patients with Psoriatic Arthritis
Led by Johnson & Johnson Private Limited · Updated on 2026-08-28
100
Participants Needed
11
Research Sites
14 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and effectiveness of guselkumab treatment in adults with psoriatic arthritis who have not sufficiently responded to standard therapies. Psoriatic arthritis is a chronic autoimmune condition causing joint inflammation, and this Phase IV open-label study focuses on Indian patients to understand how guselkumab works for them. Participants will receive subcutaneous injections of guselkumab at Weeks 0, 4, 12, and 20. The study monitors safety by recording adverse events up to 32 weeks and assesses efficacy through responses measured at Weeks 12 and 24, including changes in inflammation markers. Throughout the study, participants will undergo medical evaluations including tuberculosis screening, physical exams, ECGs, and blood tests. Researchers will track joint symptoms, inflammation levels, and any side effects. The overall participation lasts up to 32 weeks, during which safety and treatment response are carefully monitored.
CONDITIONS
Brief Title
A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)
Research Team
S
Study Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here